Nomura Holdings
CRBP icon

Nomura Holdings’s Corbus Pharmaceuticals CRBP Stock Holding History

Nomura Holdings’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-423
Closed -$36K – 1211
2016
Q2 		$36K Buy
+423
New +$33.2K ﹤0.01% 1173

Other funds holding CRBP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
CI
Conning Inc Hartford, Connecticut $3.01B AUM 16.23% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Nomura Holdings's CRBP Position: Q3 2016 in Review

Nomura Holdings sold out of Corbus Pharmaceuticals (CRBP) in Q3 2016, closing a stake of 423 shares — an estimated $36K sold.

Nomura Holdings first reported a position in CRBP in Q2 2016 and held it in 1 quarter. The position peaked at $36K in Q2 2016. 40 funds tracked by Wall St. Rank hold CRBP as of Q3 2016.

  • Nomura Holdings reported no remaining Corbus Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Nomura Holdings sold 423 Corbus Pharmaceuticals shares in Q3 2016, an estimated $36K.
  • Nomura Holdings first reported a position in Corbus Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Nomura Holdings's Corbus Pharmaceuticals position peaked at $36K in Q2 2016.
  • 40 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2016.

Based on Nomura Holdings's 13F filing for Q3 2016, filed 14 Nov 2016.